• Indivior disclosed results from two retrospective real-world studies that have already been published, linking adherence to its monthly injectable buprenorphine (Sublocade) to improved outcomes in opioid use disorder.
• In a claims-based analysis, patients who stayed on the monthly injection showed a lower likelihood of returning to opioid use than patients on other medication-assisted treatment approaches.
• A separate cohort study found patients on the monthly injection had fewer serious infection complications than those treated with daily oral buprenorphine.
• The same analysis also associated the monthly injection with reduced use of inpatient care, emergency departments, and outpatient services, pointing to potential payer and provider cost implications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605200900PRIMZONEFULLFEED1001183062) on May 20, 2026, and is solely responsible for the information contained therein.